Pediatric CIMT at both moderate and high dosages produced positive effects across multiple reliable, valid outcome measures. The findings refuted the hypothesis of differential dosage benefits. Future research should address long-term effects, enroll larger and more diverse samples, and assess lower dosages to ascertain a minimal-efficacy threshold.
No takes yet. Share an insight, caveat, or question.
DeLuca et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: